Stock Traders Purchase High Volume of Put Options on Bausch Health Cos (NYSE:BHC)

Posted by Francis Steltz on Oct 8th, 2026

Bausch Health Cos Inc. (NYSE:BHC – Get Free Report) saw some unusual options trading activity on Thursday. Traders purchased 6,766 put options on the company. This represents an increase of 164% compared to the typical volume of 2,562 put options.

Bausch Health Cos Price Performance

NYSE BHC traded down $0.04 during trading hours on Thursday, reaching $6.11. The company’s stock had a trading volume of 306,645 shares, compared to its average volume of 2,501,388. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -2.07 and a beta of 0.37. The company’s 50-day moving average is $6.21 and its two-hundred day moving average is $5.55. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $8.00.

Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%. Equities analysts forecast that Bausch Health Cos will post 4.35 EPS for the current fiscal year.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the sale, the insider directly owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. This represents a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bausch Health Cos

Large investors have recently added to or reduced their stakes in the stock. Roxbury Financial LLC acquired a new stake in Bausch Health Cos in the 3rd quarter worth about $28,000. Tacita Capital Inc acquired a new stake in Bausch Health Cos during the 2nd quarter worth $29,000. Caitong International Asset Management Co. Ltd boosted its stake in Bausch Health Cos by 25,689.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,058 shares of the company’s stock worth $70,000 after purchasing an additional 10,019 shares during the last quarter. MQS Management LLC purchased a new stake in shares of Bausch Health Cos during the first quarter worth $94,000. Finally, Viewpoint Capital Management LLC acquired a new stake in shares of Bausch Health Cos in the first quarter valued at about $97,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of recent research reports. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research note on Wednesday, July 22nd. Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $9.00 target price on shares of Bausch Health Cos in a report on Thursday. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Zacks Research raised Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Check Out Our Latest Analysis on Bausch Health Cos

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.